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Abstract: Murine neuroblastoma cells (clone N 1 E-115) pos- 
sess neurotensin receptors that mediate cyclic GMP synthe- 
sis. Because of the hypothesized relationship between phos- 
pholipid metabolism, intracellular Ca2+, and cyclic GMP 
synthesis, we determined with these cells the effects of neu- 
rotensin on 32P labeling of phospholipids, release of inositol 
phosphates, and intracellular Ca2+ (as determined with the 
use of Quin-2, a fluorescent probe sensitive to free Ca2+ 
levels). Neurotensin stimulated incorporation of "P into 
phospholipids, especially phosphatidylinositol and phos- 
phatidate. Neurotensin also stimulated the release of t3H]- 
inositol phosphates with an EC5o of about 1 nM. Mean basal 
Ca2+ concentration in these cells was 134 nM and this level 
was increased in a rapid and dose-dependent manner by 
neurotensin, with an ECso of 4 nM. Since the EC5,, for neu- 
rotensin in stimulating cyclic GMP synthesis is 1.5 nM and 
the K,, for binding of ['Hlneurotensin at 0°C is 11  nM, all 
these different effects appear to be shared proximal conse- 
quences of neurotensin receptor activation. Key Words: 
Neurotensin-Inositol phosphate-Cyclic GMP-N 1 E- 
I 15. Snider R. M. et al. Neurotensin stimulates inositol 
phospholipid metabolism and calcium mobilization in mu- 
rine neuroblastoma clone N 1 E- I 15. J. Neurochem. 47, 
12 14- 12 18 ( 1986). 
Neurotensin is a basic tridecapeptide (pGlu-Leu- 
Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) that 
is localized in a wide range of CNS and peripheral tis- 
sues and has been shown to be implicated in a variety 
of physiological processes (Nemeroff and Prange, 
1982; Goedert, 1984). Neurotensin-like immunoreac- 
tivity has been demonstrated in nerve terminals (see 
Uhl, 1982; Kahn et al., 1982) and neurotensin recep- 
tors have been localized in regions of the CNS (Uhl, 
1982; Kanba et al., 1986). Neurotensin was recently 
shown to stimulate cyclic GMP formation (Gilbert et 
al., 1984) and inositol phospholipid hydrolysis (Goed- 
ert et al., 1984) in rat brain, confirming the existence 
of functional receptors for this peptide in the mamma- 
lian CNS. 
GMP synthesis (Gilbert and Richelson, 1984). Data 
from binding studies with radiolabeled neurotensin 
correlate well with measurements of cyclic GMP re- 
sponse for neurotensin as well as for several structural 
analogs of this peptide (Gilbert et al., 1986). Since it 
has been reported that many of the receptors that 
stimulate cyclic GMP formation also are effective in 
the activation of inositol phospholipid turnover (Ber- 
ridge, 198 l), we investigated the effect of neurotensin 
on inositol phospholipid metabolism and on Ca2+ 
mobilization (as measured with Quin-2) in N 1E- 1 15 
cells. 
MATERIALS AND METHODS 
Neuroblastoma clone N 1E- 1 15 is a widely studied 
neuronal clone that possesses a neurotensin receptor 
that mediates the stimulation of intracellular cyclic 
Cell culture 
Murine neuroblastoma cells (clone N 1 E- I 15) were cul- 
tured in medium I consisting of Dulbecco's modified Eagle's 
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medium (GIBCO, Grand Island, NY, U.S.A.) without anti- 
biotics and supplemented with 10% (vol/vol) fetal bovine 
serum (GIBCO). Cells (subculture numbers 9-16) were 
grown for 10-2 1 days in 20 ml of medium I in 75-cm2/250- 
ml tissue culture flasks (Corning Glass Works, Corning, 
NY, U.S.A.) in an atmosphere of 10% c02/90% humidified 
air at 37°C. Subculture was achieved by aspirating medium 
I, and detaching the cells by incubation in modified Puck's 
D1 solution followed by centrifugation of the cell suspension 
for 2 min at 300 g. The supernatant was removed and the 
cells resuspended in 10 ml of medium I which was then in- 
oculated into flasks to give 4-8 X lo5 cells/flask on day 0. 
The culture medium was changed on days 4 and 6 and daily 
thereafter by addition of 10 ml of fresh medium I and re- 
moval of 10 ml of medium I. 
Cell labeling with 32P and lipid extraction 
Cells were isolated from tissue culture flasks in modified 
Puck's D1 solution as described above. The cells were pel- 
leted by centrifugation (300 g, 2 rnin), the supernatant aspi- 
rated, and the cell pellet washed twice in phosphate-free 
physiological saline solution (solution I) of the following 
composition: I42 mMNaC1, 5.6 mM KCl, 1 .O mM MgCI2, 
2.2 mM CaC12, 3.6 mM NaHC03, 30 mM N-2-hydroxy- 
ethylpiperazine-"-2-ethanesulfonic acid (HEPES), I 1.2 
mM glucose. Solution I was adjusted before use to pH 7.4 
and 340 mOsmol. On resuspension in solution I, viable cells 
were enumerated by trypan blue dye exclusion. The cells 
were then diluted in solution I to about 800,000 cells/ml 
and distributed in 350-pl portions into 10 X 75 mm plastic 
test tubes containing [32P]orthophosphate (carrier-free, 
Amersham, Arlington Heights, IL, U.S.A.) and neurotensin 
(Boehringer Mannheim Biochemicals, Indianapolis, IN, 
U.S.A.) in a final reaction volume of 500 pl at 37°C. The 
reactions were terminated after an incubation of 30 rnin 
with agonist by transferring the contents of each tube to a 
16 X 125 mm glass test tube containing 1.5 ml of chloro- 
form/methanol(1:2, vol/vol). The tubes were stored on ice 
for 30-60 min, after which time 0.5 ml of 2.4 A4 HCI and 
1 .O ml of chloroform were added. The tubes were vigorously 
vortex-mixed for 20-30 s and the phases separated by cen- 
trifugation. The chloroform layer was removed with a Pas- 
teur pipet, and the aqueous layer and cell debris were ex- 
tracted with an additional 1 .O ml of chloroform. After cen- 
trifugation, the chloroform layers were combined and 
washed with 2.25 ml of water/methanol/2.4 M HCl ( I :  I :  
0.25). The tubes were vortex-mixed and centrifuged, and 
the aqueous (upper) layer was aspirated and discarded. The 
volume of the chloroform layer was measured and a portion 
(50-200 pl) was counted to estimate recovery following 
TLC. The remaining chloroform layer was evaporated un- 
der a stream of nitrogen and mild heating. The residue was 
redissolved in 80 p1 of chloroform/methanol(2: I )  and spot- 
ted onto TLC plates (Merck, Darmstadt; silica gel 60, 20 
X 20 X 0.025 cm) that had previously been run in a solution 
containing 1.2 g potassium oxalate in 40 ml of methanol 
and 60 ml of water, then activated immediately before use 
by heating for 15 rnin at 1 10°C. Separation of the phospho- 
lipids was achieved by developing the plates in one dimen- 
sion for 1-1 .5 h in chloroform/acetone/methanol/glacial 
acetic acid/water (40: 15: 13: 12:7). After TLC, the labeled 
phospholipids were localized by autoradiography with the 
use of Kodak XRP-5 film (exposure time approximately 16 
h). For quantitation, the areas on the TLC plates corre- 
sponding to lipids of interest were scraped and counted for 
radioactivity. The data for phosphatidate (PA), phosphati- 
dylinositol (PI), phosphatidylinositol 4-phosphate (PIP), 
and phosphatidylinositol4,5-bisphosphate (PIP2) were cor- 
rected for recovery of total lipids before analysis. 
Assay for the release of [3Hi]inositol phosphates 
Confluent cells in one flask (250-m1/75-cmz) were col- 
lected as described above, washed, and suspended in 2 ml 
of solution 11, consisting of I10 mMNaC1, 5.3 mMKC1, I .8 
mM CaClz, 1.0 mM MgCI2, 2.0 mM Na2HP04, 25 mM 
glucose, and 70 mM sucrose (pH 7.35 and 340 mOsmol) 
to which was added 50 pCi rny~-[~H]inositol ( I  5 Ci/mmol; 
American Radiolabelled Chemicals, St. Louis, MO, 
U.S.A.). This suspension was then incubated for 60 min at 
37°C in a shaking water bath. At the end of this incubation 
period, cells were centrifuged and the supernatant was aspi- 
rated to remove excess radiolabel. The cells were then sus- 
pended in solution I1 to give about 6 X lo5 cells/ml. Ali- 
quots of 2 10 pl of this suspension were added to glass tubes 
( 1 3 x 100 mm) containing 30 pl of 100 mM LiCl and incu- 
bated at 37°C in a shaking water bath. After a 30-min equili- 
bration period, neurotensin in 60 pl of solution I1 was added 
and after 10 min, the reaction was stopped with the addition 
of 750 p1 of chloroform/methanol(l:2). Each tube was then 
vortex-mixed and placed on ice. The phases were formed by 
the addition of 250 pl of chloroform and 250 pl of an aque- 
ous solution containing ~-myo-[  ''C]inositol I-phosphate 
(about 0.7 nCi, 55 mCi/mmol; Amersham) as an internal 
standard. After further vortex-mixing, the tubes were centn- 
fuged at about 400 g for 5 min. A portion (600 pl) of the 
upper phase was transferred to a polystyrene (12 X 75 mm) 
tube that contained 2 ml of water. This solution was then 
applied to an AG 1-X8, 100-200 mesh, column (0.6 X 1.0 
cm; converted to the formate form; Bio-Rad Laboratories, 
Richmond, CA, U.S.A.) and the inositol phosphates were 
eluted as described by Bemdge et al. (1983). Thus, to this 
column was added 20 ml of 60 mM ammonium formate/5 
mMsodium tetraborate, and the eluate was discarded. Total 
[3H]inositol phosphates were then eluted with 4 ml of I M 
ammonium forrnate/lOO mM formic acid. The eluate was 
combined with 16 ml of Safety Solve (RPI, Mount Prospect, 
IL, U.S.A.) and the radioactivity was determined by liquid 
scintillation spectrometry. Data were analyzed by computer 
and corrected for recovery of [14C]inositol I-phosphate 
which was about 50%. 
Quin-2 loading and measurement of [Ca2+Ii 
Cells were isolated as described above, resuspended in so- 
lution I ( 1  X 10' cells/ml; total volume 7-8 ml), and incu- 
bated with Quin-2 acetoxymethyl ester (Calbiochem-Beh- 
ring; 50 p M )  for 30 rnin at 37°C in a shaking water bath. 
The cells were then diluted threefold and allowed to incu- 
bate 15-30 rnin longer at 37°C. After gentle centrifugation 
(300 g, 2 rnin), the supernatant was removed, and the cells 
were resuspended in fresh solution I ( I  X lo6 cells/ml) and 
kept at room temperature. Immediately before use, a I-ml 
portion of the cellular suspension was centrifuged, the su- 
pernatant was removed, and the pellet was resuspended in 
fresh solution I to remove any extracellular Quin-2. Fluores- 
cence measurements were made at 37°C with constant stir- 
ring in an Aminco-Bowman Spectrophotofluorometer 
(American Instruments, Silver Springs, MD, U.S.A.); exci- 
tation 339, emission 490 nm. Quantitation of calcium con- 
centrations in intact cells was camed out as described by 
Tsien et al. (1982). 
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RESULTS 
Stimulation of [32P]inositol ipid labeling by 
neurotensin 
When neuroblastoma cells were incubated under 
conditions in which neurotensin was added at the be- 
ginning of the incubation period together with 32P 
(carrier-free), there was a substantial increase in the 
amount of 32P localized in PI and PA (Table 1). Rela- 
tively minor changes were observed in PIP and PIP2 
(Table 1) whereas no alterations in the labeling of 
the quantitatively major phospholipids (phosphati- 
dylethanolamine, -choline, and -serine) were found 
(data not shown). 
Stimulation of the release of [3H]inositol phosphates 
by neurotensin 
The above results indirectly indicated that neuro- 
tensin stimulated the cleavage of inositol phosphates 
from phospholipids of N 1 E- 1 15 cells. To obtain direct 
evidence for this mechanism, we tested the capacity 
of neurotensin to stimulate the release of [3H]inositol 
phosphates from cells that had been prelabeled with 
rny~-[~H]inositol. Neurotensin rapidly stimulated this 
release, with peak responses occurring by about 2 min 
(Fig. 1). Dose-response curves for neurotensin and re- 
lease of [3H]inositol phosphates (Fig. 2) yielded an 
ECS0 * SEM = 0.9 f 0.6 nM(n = 4) for this peptide. 
Neurotensin at a maximal concentration (lo-' M )  in- 
creased release of [ 3H]inositol phosphates over basal 
in the range of 50% at an incubation time with agonist 
of 10 min. 
Effects of neurotensin on [Ca2+Ii 
Receptors that stimulate the turnover of inositol 
phospholipids also increase the intracellular concen- 
tration of Ca2+. With the use of Quin-2, a calcium- 
sensitive fluorescent probe (Tsien et al., 1982), we 
found that neurotensin caused an increase in intracel- 
lular Ca2+ (Figs. 3 and 4). Mean basal [Ca2+Ii f SEM 
was 134 k 7 nM(n = 17) and the ECS0 for neurotensin 
determined from a dose-response experiment (Fig. 4) 
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FIG. 1. Time course for neurotensin-stimulated release of [3H]- 
inositol phosphates. Neurotensin (1 0 nM) was incubated with 
cells (about 100,00O/tube) prelabeled with rny~-[~H]inositol as de- 
scribed in Materials and Methods for the indicated times and re- 
lease of [3H]inositol phosphates was measured. Unstimulated lev- 
els of release of [3H]inositol phosphates at each time point 
(around 15,000 dpm/lO' cells) have been subtracted. Data are 
from one of two independent time-course experiments, each 
point of which was determined in triplicate. 
concentration elicited a reproducible elevation in 
[Ca2+Ii (Fig. 3). A 10-fold higher concentration of the 
peptide caused a rapid desensitization of the neuro- 
tensin receptor. 
DISCUSSION 
These data show that neurotensin, presumably by 
activating its receptors on clone N1E-115, stimulated 
inositol phospholipid metabolism and increased 
[Ca2+Ii with similar dose-response profiles. Pre- 
TABLE 1. Neurotensin-stimulated changes in "P 
radioactivity in phospholipids 
32P Radioactivity" 
Control Neurotensin ( w ' M )  
PIP2 22,000 f 700 26,000 * 3,000 
PIP 6,600 k 200 8,OOOk 800 
PI 6,000 k 600 14,500 +- l,OOOb 
PA 6,800 k 300 13,700 * 6006 
' De novo phospholipid labeling was camed out for 30 min as 
described in Materials and Methods. The radioactivity in the lipids 
shown accounts for 80-85% of the total radioactivity in the lipid 
extract. Values given are the X k SEM of four separate experiments. 
p < 0.0 1 compared to control. 
1 i  10 9 8 7 
-Log [neurotensin] (M) 
FIG. 2. Dose-response for neurotensin-stimulated release of 
[3H]inositol phosphates from clone N1 E-115 cells. Neurotensin at 
the indicated concentrations was incubated for 10 min with cells 
prelabeled with rny~-[~H]inositol as described in Materials and 
Methods and release of [3H]inositol phosphates was measured. 
Release in the absence of neurotensin (40,000 dpm/l O'cefls) has 
been subtracted from each point. Data are representative results 
from one of four independent dose-response experiments, each 
experimental point determined in triplicate. 
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FIG. 3. Neurotensin-mediated increases in intracellular Ca" of 
N1E-115 cells loaded with Quin-2. Changes in the fluorescence 
intensity of Quin-2 were taken as a measure of the concentration 
of intracellular Ca" as described by Tsien et al. (1 982). 
viously, we showed that neurotensin acting on N1 E- 
115 cells and on rat brain slices also mediates cyclic 
GMP synthesis (Gilbert and Richelson, 1984; Gilbert 
et al., 1984, 1986), the first known biochemical event 
associated with neurotensin receptors. In addition, 
Goedert et al. (1 984) showed that neurotensin stimu- 
lates the release of inositol phosphate in rat brain 
slices. All these data support the hypothesis that this 
tridecapeptide serves as a neurotransmitter or neuro- 
modulator in the nervous system. 
As is the case for the effects of a diverse group of 
agents, the effects of neurotensin on its receptor ap- 
pear to result in the breakdown of inositol lipids and 
mobilization of Ca" as early events (Berridge and Ir- 
vine, 1984). In N 1 E- 1 1 5 cells neurotensin stimulated 
labeling of 32Pi primarily into PA and PI (Table 1). 
These data suggest that, as in other tissues, breakdown 
of polyphosphoinositides precedes stimulated label- 
I I I I 
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FIG. 4. Dose-response for neurotensin and the increase in intra- 
cellular Ca2+ of N1 E-115 cells. Cells loaded with Quin-2 were incu- 
bated with the indicated concentrations of neurotensin and the 
increase in intracellular Ca2+ was calculated from the peak of the 
increases in fluorescence (Tsien et al., 1982). For each concentra- 
tion, from three to six different groups of cells were tested. Means 
k SEM are presented. 
ing of PI and PA, which labeling can be regarded as 
the restorative phase of a closed cycle that eventually 
resynthesizes PIP2. Receptor-stimulated release of 
[3H]inositol phosphates from prelabeled NlE- 1 15 
cells provided more direct evidence of the phospho- 
diesteratic cleavage of phosphoinositides. 
The dose-response relationships for neurotensin's 
stimulation of the release of [3H]inositol phosphates 
and the increase in [Ca2+Ii were within the same range 
(Figs. 2 and 4). Since the KD for [3H]neurotensin and 
its receptors on these cells is 1 1 nM at 0°C (Gilbert et 
al., 1986) and the ECso for stimulation of intracellular 
cyclic GMP formation is 1.5 nM, these events appear 
to be mediated by the same receptor site and may con- 
stitute early consequences of neurotensin receptor ac- 
tivation. 
Of interest is the relationship between the release of 
inositol phosphates, the rise in intracellular Ca2+, and 
the increased synthesis of cyclic GMP. It has long 
been hypothesized that increased intracellular Ca2+ 
stimulates guanylate cyclase, the enzyme that synthe- 
sizes cyclic GMP from GTP (Richelson and El-Faka- 
hany, 198 1). Some of the evidence in support of a di- 
rect role for (.a2+ in receptor-mediated cyclic GMP 
synthesis is that this response is absolutely dependent 
on the presence of extracellular Ca2+, and guanylate 
cyclase in these cells is largely a soluble enzyme and 
is stimulated by this cation (Bartfai et al., 1978). In 
addition, our results showing that receptor-mediated 
inositol phosphate release in clone N 1 E- 1 15 cells is 
also dependent on extracellular Ca2+ (Forray et al., 
manuscript in preparation) suggests a link between re- 
lease of inositol phosphates, Ca2+ mobilization, and 
cyclic GMP synthesis. 
However, previously we proposed (Snider et al., 
1984) that neurotransmitters mediate cyclic GMP 
synthesis by stimulating the release of arachidonic 
acid from phospholipids (possibly by activating phos- 
pholipase A*) followed by the metabolism of arachi- 
donic acid by lipoxygenase(s) to a product that stimu- 
lates guanylate cyclase. Thus, for example, eicosatet- 
raynoic acid (ETYA), a lipoxygenase inhibitor, blocks 
receptor-mediated cyclic GMP synthesis in clone 
NlE-115 cells (Snider et al., 1984), but has little effect 
on receptor-mediated release of inositol phosphates in 
these cells (McKinney and Richelson, 1986). There- 
fore, it is likely that release of inositol phosphates and 
the probable subsequent rise of [Ca2+li are not suffi- 
cient for receptor-mediated cyclic GMP synthesis. 
In conclusion, our data show that the neurotensin- 
induced increases of [3H]inositol phosphates, intracel- 
lular Ca2+, and cyclic GMP all occurred within a sim- 
ilar time frame and with similar dose-response 
curves. However, we can draw no inference yet from 
these studies as to the sequential or causative relation- 
ships of these events. 
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